Mimetogen Pharmaceuticals, Inc.

Aldeyra Therapeutics, Inc. ’s reproxalap has shown significant symptom improvement over Novartis AG ’s Xiidra in a Phase II dry eye trial, prompting the firm to tout its potential as a first-line tre

Ocugen Inc. says it is ready to take its combination product OCU310 into Phase III after unveiling top-line Phase II data demonstrating tolerability of the two-drug combo. Promising trends for signs

While Allergan PLC and Shire PLC are jockeying for supremacy in the dry eye disease space, with the former's Restasis (cyclosporine ophthalmic emulsion) losing market share to the latter's

If Pfizer Inc. President-Worldwide R&D Mikael Dolsten and Allergan PLC Exec VP Brand R&D David Nicholson are to be believed, the two companies’ research organizations are about to be united in